Rick Pieschl
Overview
Explore the profile of Rick Pieschl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
148
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Luo G, Chen L, Kostich W, Hamman B, Allen J, Easton A, et al.
J Med Chem
. 2022 Mar;
65(6):4534-4564.
PMID: 35261239
Recent mouse knockout studies identified adapter protein-2-associated kinase 1 (AAK1) as a viable target for treating neuropathic pain. BMS-986176/LX-9211 (), as a highly selective, CNS-penetrable, and potent AAK1 inhibitor, has...
2.
Luo G, Chen L, Kostich W, Hamman B, Allen J, Easton A, et al.
J Med Chem
. 2022 Mar;
65(6):4457-4480.
PMID: 35257579
Recent mouse knockout studies identified adapter protein-2 associated kinase 1 (AAK1) as a viable target for treating neuropathic pain. Potent small-molecule inhibitors of AAK1 have been identified and show efficacy...
3.
Roy J, Warner B, Basuli F, Zhang X, Zheng C, Goldsmith C, et al.
EJNMMI Res
. 2021 Jul;
11(1):66.
PMID: 34287731
Background: PSMA-targeted radionuclide therapy (TRT) is a promising treatment for prostate cancer (PCa), but dose-limiting xerostomia can severely limit its clinical adaptation, especially when using alpha-emitting radionuclides. With [F]DCFPyL as...
4.
Tang H, Kukral D, Li Y, Fronheiser M, Malone H, Pena A, et al.
J Psychopharmacol
. 2018 Jan;
32(2):146-155.
PMID: 29378483
Major depressive disorder is a leading cause of disability globally. Improvements in the efficacy of antidepressant therapy are needed as a high proportion (>40%) of individuals with major depressive disorder...
5.
Bristow L, Gulia J, Weed M, Srikumar B, Li Y, Graef J, et al.
J Pharmacol Exp Ther
. 2017 Sep;
363(3):377-393.
PMID: 28954811
()-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169) and the phosphate prodrug 4-((3,4)-3-fluoro-1-((R)-1-(4-methylbenzyl)-2-oxopyrrolidin-3-yl)piperidin-4-yl)phenyl dihydrogen phosphate (BMS-986163) were identified from a drug discovery effort focused on the development of novel, intravenous glutamate -methyl-d-aspartate 2B receptor (GluN2B) negative...
6.
Wu Y, Guernon J, McClure A, Luo G, Rajamani R, Ng A, et al.
Bioorg Med Chem
. 2017 Aug;
25(20):5490-5505.
PMID: 28818462
Since zwitterionic benzenesulfonamide Na1.7 inhibitors suffer from poor membrane permeability, we sought to eliminate this characteristic by replacing the basic moiety with non-basic bicyclic acetals and monocyclic ethers. These efforts...
7.
Louis J, Lu Y, Pieschl R, Tian Y, Hong Y, Dandapani K, et al.
Neuropharmacology
. 2017 Mar;
118:167-174.
PMID: 28315351
Adaptor-associated kinase 1 (AAK1), a member of the Ark1/Prk1 family of serine/threonine kinases, plays a role in modulating clatherin coated endocytosis of specific surface receptors. We have demonstrated that AAK1...
8.
Kostich W, Hamman B, Li Y, Naidu S, Dandapani K, Feng J, et al.
J Pharmacol Exp Ther
. 2016 Jul;
358(3):371-86.
PMID: 27411717
To identify novel targets for neuropathic pain, 3097 mouse knockout lines were tested in acute and persistent pain behavior assays. One of the lines from this screen, which contained a...
9.
Fernandes A, Wojcik T, Baireddy P, Pieschl R, Newton A, Tian Y, et al.
Eur J Pharmacol
. 2015 Sep;
766:1-8.
PMID: 26325093
N-methyl-D-aspartate (NMDA) receptor antagonists, including open channel blockers and GluN2B receptor subtype selective antagonists, have been developed for the treatment of depression. The current study investigated effects of systemically administered...
10.
Graef J, Newberry K, Newton A, Pieschl R, Shields E, Luan F, et al.
Brain Res
. 2015 Mar;
1609:31-9.
PMID: 25796435
The long lasting antidepressant response seen following acute, i.v. ketamine administration in patients with treatment-resistant depression (TRD) is thought to result from enhanced synaptic plasticity in cortical and hippocampal circuits....